Infectio最新文献_第9页

Colombian HIV/AIDS registry and health risk management 哥伦比亚艾滋病毒/艾滋病登记和健康风险管理

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1009

Julieth Carolina Castillo-Cañón, Silvia Juliana Trujillo-Cáceres, C. Álvarez-Moreno, A. Valbuena-Garcia, Ricardo Luque-Núñez, C. Ríos-Hincapié, L. Acuña-Merchán

{"title":"Colombian HIV/AIDS registry and health risk management","authors":"Julieth Carolina Castillo-Cañón, Silvia Juliana Trujillo-Cáceres, C. Álvarez-Moreno, A. Valbuena-Garcia, Ricardo Luque-Núñez, C. Ríos-Hincapié, L. Acuña-Merchán","doi":"10.22354/IN.V26I2.1009","DOIUrl":"https://doi.org/10.22354/IN.V26I2.1009","url":null,"abstract":"HIV/AIDS information systems are a critical tool for keeping track of the HIV pandemic in any country, leading to the AIDS elimination to 2030 and achievement of the 95-95-95 goals set by 2025. In this article, we describe the data management process of the Colombian National HIV/AIDS registry, its epidemiological results and contributions to research and health risk management. This registry is a longitudinal database. Variables and periodicity are defined by The Ministry of Health and Social Protection. Reporting is done by health insurers and their healthcare providers on annual bases. The information is uploaded through a web platform run by the High-Cost Diseases Fund, in charge of the validation, auditing process, consolidation, analysis and publication of the data. Security and confidentiality of the information is also taken care of by the High-Cost Disease Fund. Main results include epidemiological follow up of the epidemic, periodic evaluation of 25 risk management indicators, publication of research studies and the calculation of an economic incentive for insurers to improve health risk management. The registry has shown to be useful not only for the management of clinical information but also for administrative purposes.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43177996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Contribución del uso de XPERT MTB/RIF y su costo-efectividad en el diagnóstico de tuberculosis pulmonar y la resistencia a rifampicina: una comparación con métodos diagnósticos no moleculares 使用XPERT MTB/RIF的贡献及其在肺结核和利福平耐药性诊断中的成本效益:与非分子诊断方法的比较

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1010

C. Cadavid, Teresa Realpe, G. Mejía, E. Zapata, Mauricio Hernández, Jaime Robledo

{"title":"Contribución del uso de XPERT MTB/RIF y su costo-efectividad en el diagnóstico de tuberculosis pulmonar y la resistencia a rifampicina: una comparación con métodos diagnósticos no moleculares","authors":"C. Cadavid, Teresa Realpe, G. Mejía, E. Zapata, Mauricio Hernández, Jaime Robledo","doi":"10.22354/IN.V26I2.1010","DOIUrl":"https://doi.org/10.22354/IN.V26I2.1010","url":null,"abstract":"Introducción: La tuberculosis es un problema de salud pública; su control requiere diagnóstico temprano y tratamiento oportuno. Xpert MTB/RIF® es una tecnología diagnóstica basada en PCR en tiempo real, detecta el Complejo Mycobacterium tuberculosis y la susceptibilidad a rifampicina. Objetivo: Determinar la contribución del Xpert MTB/RIF y su costo-efectividad en la detección de tuberculosis y la resistencia a rifampicina en muestras respiratorias al compararlo con métodos de diagnóstico no moleculares. Materiales y Métodos: Se analizaron 1.574 muestras de pacientes con sospecha de tuberculosis pulmonar que fueron procesadas para microscopía con coloración fluorescente de auramina-rodamina, Xpert MTB/RIF y cultivo en BACTEC MGIT 960. Los resultados obtenidos se compararon entre los métodos no moleculares y los moleculares para la detección de M. tuberculosis y susceptibilidad a rifampicina y se realizó un análisis comparativo de costos y costo efectividad. Resultados: 19,2% de las muestras fueron positivas por alguna de las técnicas usadas. Xpert MTB/RIF detectó M. tuberculosis en 90,4% del total de muestras positivas con un índice Kappa de 0,77 (IC95%: 0,74-0,82) comparado con el cultivo. La resistencia a rifampicina por Xpert fue 8,1%, sensibilidad 94,1% (IC95%: 73,0–99,0%), especificidad 98,4% (IC95%: 95,5–99,5%) y Kappa de 0,88 (IC95%: 0,76-1,00). La razón incremental de costo efectividad (RICE) fue menor en Xpert MTB/RIF comparada con el cultivo. Conclusión: Xpert MTB/RIF es una prueba eficiente y costo efectiva en la detección de casos de M. tuberculosis en muestras pulmonares comparado con los métodos de diagnóstico basados en cultivo, sin embargo y a diferencia del Xpert MTB/RIF, estos pueden aportar en el diagnóstico con el aislamiento de especies de micobacterias no tuberculosas y la susceptibilidad a isoniazida y otros medicamentos.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48838700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molusco contagioso del párpado: manifestación cutánea de inmunosupresión 眼睑传染性软体动物:免疫抑制的皮肤表现

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1020

C. Morales-Cardona, Mariana Romero-Porras

引用次数: 0

Infección de cavidad anoftálmica por Scedosporium sp. en paciente inmunocompetente: Reporte de caso 免疫功能正常患者无眼球腔感染Scedosporium sp.病例报告

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1021

Claudia Martínez-Córdoba, Lina Muñoz-Salazar, Carlos Contreras-Vargas, Luis Alberto Ruiz-Robles

引用次数: 0

Material suplementario. Enfermedad de Kawasaki, enfermedad similar a Kawasaki y MIS-C asociado a COVID-19 en niños: revisión sistemática 补充材料。儿童与COVID-19相关的川崎病、川崎样病和misc:系统综述

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1012

Joshuan J. Barboza, Diego Chambergo-Michilot, M. Velásquez-Sotomayor, Christian Silva-Rengifo, Christoper A. Alarcón-Ruiz, A. RodrÍguez-Morales, Germán Málaga, Giordano Pérez-Gaxiola

引用次数: 2

Cambio en la mortalidad intrahospitalaria durante el primer pico por SARS- COV-2 en Bogotá, Colombia 哥伦比亚波哥大SARS-CoV-2首次高峰期间住院死亡率的变化

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1015

Stephany Barbosa, Ó. Muñoz, Alejandra Cañas Arboleda, A. A. García, Peter Olejua, Melissa Díaz

{"title":"Cambio en la mortalidad intrahospitalaria durante el primer pico por SARS- COV-2 en Bogotá, Colombia","authors":"Stephany Barbosa, Ó. Muñoz, Alejandra Cañas Arboleda, A. A. García, Peter Olejua, Melissa Díaz","doi":"10.22354/IN.V26I2.1015","DOIUrl":"https://doi.org/10.22354/IN.V26I2.1015","url":null,"abstract":"Introducción: La mortalidad por SARS-COV-2 ha disminuido en diferentes países, pero no se ha evaluado si es igual en Colombia, o si se relaciona con las características de los pacientes y tratamientos utilizados. Objetivo: Comparar la mortalidad por SARS-COV-2, en dos periodos de tiempo controlando por factores de riesgo asociados con mortalidad. Metodología: Estudio observacional, basado en una cohorte retrospectiva de pacientes con SARS-COV-2 atendidos en el Hospital Universitario San Ignacio, Bogotá (Colombia), desde el 19 de marzo al 12 de noviembre, 2020. Se comparó la tasa de mortalidad intrahospitalaria de los pacientes egresados antes y después del 21 de agosto de 2020 (primer pico de mortalidad en Colombia) y se analizó el impacto del momento de atención controlando por comorbilidades, severidad al ingreso y tratamiento recibido, usando un modelo de regresión logística. Resultados: 1399 pacientes (944 antes y 455 después del primer pico de mortalidad) fueron analizados. La tasa de mortalidad intrahospitalaria global fue similar en ambos periodos (17.6% vs 16.3%, p=0.539). En el análisis multivariado se encontró que la atención en el segundo periodo de tiempo se asoció a menor mortalidad (OR 0.66 IC95% 0.47; 0.93, p=0.018), a diferencia del aumento de la misma asociado a la edad (OR 1.06 IC95% 1.05; 1.07, p<0.001), sexo masculino (OR 1.84 IC95% 1.33; 2.54 p<0.001), cirrosis (OR 1.89 IC95% 1.24; 2.88, p=0.003), enfermedad renal (OR 1.36 IC95% 1.00; 1.83, p=0.043) y el uso de dexametasona (OR 1.53 IC95% 1.03; 2.28, p=0.031). Conclusiones: La tasa de mortalidad intrahospitalaria se redujo después del 21 de agosto durante la primera ola de la pandemia en Bogotá, posiblemente asociado a la mejoría en la capacidad de respuesta del sistema de salud en ese momento, o a un menor inoculo viral de los pacientes infectados. Estos hallazgos pueden cambiar con la saturación del sistema de salud.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48498471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Statistical analysis of 484 Mycobacterium tuberculosis genomes reveals an association between single nucleotide polymorphisms on ponA1 gene and LAM and Haarlem lineages 对484个结核分枝杆菌基因组的统计分析揭示了ponA1基因单核苷酸多态性与LAM和Haarlem谱系之间的关联

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1017

Jhonatan Rabanal, M. Zimic

{"title":"Statistical analysis of 484 Mycobacterium tuberculosis genomes reveals an association between single nucleotide polymorphisms on ponA1 gene and LAM and Haarlem lineages","authors":"Jhonatan Rabanal, M. Zimic","doi":"10.22354/IN.V26I2.1017","DOIUrl":"https://doi.org/10.22354/IN.V26I2.1017","url":null,"abstract":"Objectives: Evaluate the association between rifampicin resistance and the presence of at least one SNP in the rpoB and ponA1 genes and the spoligotype defined lineages. Material and Methods: This study analyzed two databases of 484 genomes of M. tuberculosis from strains isolated from patients in the cities of Lima and Callao, for which the odds ratio (OR) was calculated considering belonging to a certain spoligotype defined lineages as an exposure factor. Results: No statistically significant association (? value> 0.05) was found between the presence of at least one SNP in the rpoB gene and the lineages included in the study (LAM, Haarlem, T and Beijing). However, a statistically significant association was found between the presence of at least one SNP in the ponA1 gene and the LAM and Haarlem lineages (? value <0.05). An association was found between the P631S SNP in the ponA1 gene and the LAM and Haarlem lineages; and the A516T SNP, of this same gene, presented an association with the LAM lineage. Likewise, an association was found between rifampicin resistance and the LAM lineage. Conclusions: The presence of SNPs in the ponA1 gene is associated with the LAM and Haarlem lineages.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43928180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and Visions for Infectious Diseases in Colombia during the COVID-19 Peripandemic Transition 2021-2023 2021-2023年新冠肺炎大流行期间哥伦比亚传染病的挑战和展望

Infectio Pub Date : 2021-10-15 DOI: 10.22354/IN.V26I2.1007

A. Rodríguez-Morales, G. Camacho-Moreno, Henry Mendoza-Ramírez, Iván Arturo Rodríguez-Sabogal, J. Oñate

引用次数: 1

Bacterial diversity analysis of freshwater sources for human use in rural areas of the tropical Andean region of Colombia 哥伦比亚热带安第斯地区农村地区供人类使用的淡水资源的细菌多样性分析

Infectio Pub Date : 2021-08-14 DOI: 10.22354/in.v26i1.988

Katherine Bedoya, L. Galeano, M. Hincapié, J. A. Mesa, J. Alzate

引用次数: 1

The evidence of Bayesian A/B testing in the contrast of clinical events by COVID-19 贝叶斯A/B测试在COVID-19临床事件对比中的证据

Infectio Pub Date : 2021-08-14 DOI: 10.22354/in.v26i1.1003

C. Ramos-Vera

{"title":"The evidence of Bayesian A/B testing in the contrast of clinical events by COVID-19","authors":"C. Ramos-Vera","doi":"10.22354/in.v26i1.1003","DOIUrl":"https://doi.org/10.22354/in.v26i1.1003","url":null,"abstract":"Cómo citar este artículo: C. Ramos-Vera. The evidence of Bayesian A/B testing in the contrast of clinical events by COVID-19. Infectio 2022; 26(1): 99-100 Sr. Editor: The clinical investigations reported in this journal employ the standard framework of frequentist statistics based on significance assumptions (p < 0.05). This method leads to a dichotomization of the results as “significant” or “non-significant” requiring the evaluation of statistical hypotheses1. Therefore, the use of the Bayesian approach is important as an improved way of drawing statistical conclusions from clinical data since it facilitates the answer to the question, what is the probability that the effect is conclusive based on the data, which provides greater validity to the significant conclusions. One of the best known methods is the Bayes factor (FB), which estimates the probability of one hypothesis relative to the other given the data (e.g., null hypothesis vs alternate hypothesis)1,2, this allows estimation of the weight of evidence (10 times the decimal logarithm value of the FB)3,4, useful for decision making of significant findings, where results with evidence values greater than 20 are optimal for clinical decision making.","PeriodicalId":38132,"journal":{"name":"Infectio","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44004882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0